Recyte Therapeutics Overview

  • Year Founded
  • 2007

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

Recyte Therapeutics General Information

Description

Developer of regenerative medicine products intended for the treatment of vascular disorders. The company created therapeutic products that are derived from human stem cells in vitro, including from embryonic and induced pluripotent stem cell sources, providing healthcare providers with efficient therapies for cardiovascular and blood-related diseases.

Contact Information

Website
www.recyte.com
Formerly Known As
Embryome Sciences
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1301 Harbor Bay Parkway
  • Suite 100
  • Alameda, CA 94502
  • United States
+1 (510)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 1301 Harbor Bay Parkway
  • Suite 100
  • Alameda, CA 94502
  • United States
+1 (510)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Recyte Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Jan-2023 Completed Generating Revenue
1. Seed Round 24-Mar-2011 Completed Generating Revenue
To view Recyte Therapeutics’s complete valuation and funding history, request access »

Recyte Therapeutics Patents

  • 8

    Total Documents Applications and Grants

  • Total Patents Families

  • 6

    Granted

  • 2

    Pending

  • Expiring in next 12 mo

Recyte Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20160108368-A1 Exosomes from clonal progenitor cells Active 03-Jul-2014
US-20190241873-A1 Exosomes from clonal progenitor cells Active 03-Jul-2014
US-10240127-B2 Exosomes from clonal progenitor cells Active 03-Jul-2014
US-11274281-B2 Exosomes from clonal progenitor cells Active 03-Jul-2014
US-20220403341-A1 Exosomes from clonal progenitor cells Pending 03-Jul-2014 A61K35/44
To view Recyte Therapeutics’s complete patent history, request access »

Ready to get started?

Request a free trial

Recyte Therapeutics FAQs

  • When was Recyte Therapeutics founded?

    Recyte Therapeutics was founded in 2007.

  • Where is Recyte Therapeutics headquartered?

    Recyte Therapeutics is headquartered in Alameda, CA.

  • What industry is Recyte Therapeutics in?

    Recyte Therapeutics’s primary industry is Drug Discovery.

  • Is Recyte Therapeutics a private or public company?

    Recyte Therapeutics is a Private company.

  • What is Recyte Therapeutics’s current revenue?

    The current revenue for Recyte Therapeutics is .

  • How much funding has Recyte Therapeutics raised over time?

    Recyte Therapeutics has raised $10.1M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »